187 related articles for article (PubMed ID: 24236197)
1. Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway.
Nord KH; Nilsson J; Arbajian E; Vult von Steyern F; Brosjö O; Cleton-Jansen AM; Szuhai K; Hogendoorn PC
PLoS One; 2013; 8(11):e80725. PubMed ID: 24236197
[TBL] [Abstract][Full Text] [Related]
2. Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma.
Saba KH; Cornmark L; Hofvander J; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Foijer F; Staaf J; Brosjö O; Sumathi VP; Lam SW; Szuhai K; Bovée JV; Kovac M; Baumhoer D; Styring E; Nord KH
J Pathol Clin Res; 2020 Oct; 6(4):231-237. PubMed ID: 32542935
[TBL] [Abstract][Full Text] [Related]
3. Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics?
Ameline B; Nathrath M; Nord KH; de Flon FH; Bovée JVMG; Krieg AH; Höller S; Hench J; Baumhoer D
Mod Pathol; 2022 Sep; 35(9):1204-1211. PubMed ID: 35347251
[TBL] [Abstract][Full Text] [Related]
4. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.
Cleton-Jansen AM; Anninga JK; Briaire-de Bruijn IH; Romeo S; Oosting J; Egeler RM; Gelderblom H; Taminiau AH; Hogendoorn PC
Br J Cancer; 2009 Dec; 101(11):1909-18. PubMed ID: 19888226
[TBL] [Abstract][Full Text] [Related]
5. FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool.
Amary F; Markert E; Berisha F; Ye H; Gerrand C; Cool P; Tirabosco R; Lindsay D; Pillay N; O'Donnell P; Baumhoer D; Flanagan AM
Am J Surg Pathol; 2019 Dec; 43(12):1661-1667. PubMed ID: 31490237
[TBL] [Abstract][Full Text] [Related]
6. Osteoblastoma characterized by a three-way translocation: report of a case and review of the literature.
Giannico G; Holt GE; Homlar KC; Johnson J; Pinnt J; Bridge JA
Cancer Genet Cytogenet; 2009 Dec; 195(2):168-71. PubMed ID: 19963118
[TBL] [Abstract][Full Text] [Related]
7. Recurrent rearrangements of FOS and FOSB define osteoblastoma.
Fittall MW; Mifsud W; Pillay N; Ye H; Strobl AC; Verfaillie A; Demeulemeester J; Zhang L; Berisha F; Tarabichi M; Young MD; Miranda E; Tarpey PS; Tirabosco R; Amary F; Grigoriadis AE; Stratton MR; Van Loo P; Antonescu CR; Campbell PJ; Flanagan AM; Behjati S
Nat Commun; 2018 Jun; 9(1):2150. PubMed ID: 29858576
[TBL] [Abstract][Full Text] [Related]
8. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters.
Oliveira CR; Mendonça BB; Camargo OP; Pinto EM; Nascimento SA; Latorre Mdo R; Zerbini MC
Clinics (Sao Paulo); 2007 Apr; 62(2):167-74. PubMed ID: 17505702
[TBL] [Abstract][Full Text] [Related]
9. Aggressive osteoblastoma: a case report involving a unique chromosomal aberration.
Baker AC; Rezeanu L; Klein MJ; Pitt MJ; Buecker P; Hersh JH; Buchino JJ; Siegal GP
Int J Surg Pathol; 2010 Jun; 18(3):219-24. PubMed ID: 18611933
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.
Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP
Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430
[TBL] [Abstract][Full Text] [Related]
11. Role of immunohistochemical cyclo-oxygenase-2 (COX-2) and osteocalcin in differentiating between osteoblastomas and osteosarcomas.
El-Badawi ZH; Muhammad EM; Noaman HH
Malays J Pathol; 2012 Jun; 34(1):15-23. PubMed ID: 22870593
[TBL] [Abstract][Full Text] [Related]
12. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.
Lam SW; Cleven AHG; Kroon HM; Briaire-de Bruijn IH; Szuhai K; Bovée JVMG
Virchows Arch; 2020 Mar; 476(3):455-463. PubMed ID: 31768625
[TBL] [Abstract][Full Text] [Related]
13.
Panagopoulos I; Gorunova L; Lobmaier I; Andersen K; Kostolomov I; Lund-Iversen M; Bjerkehagen B; Heim S
Cancer Genomics Proteomics; 2020; 17(2):161-168. PubMed ID: 32108038
[TBL] [Abstract][Full Text] [Related]
14. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.
Both J; Krijgsman O; Bras J; Schaap GR; Baas F; Ylstra B; Hulsebos TJ
PLoS One; 2014; 9(12):e115835. PubMed ID: 25551557
[TBL] [Abstract][Full Text] [Related]
15. Benign Bone-Forming Tumors.
Amary F; Flanagan AM; O'Donnell P
Surg Pathol Clin; 2021 Dec; 14(4):549-565. PubMed ID: 34742480
[TBL] [Abstract][Full Text] [Related]
16. The genetic basis for inactivation of Wnt pathway in human osteosarcoma.
Du X; Yang J; Yang D; Tian W; Zhu Z
BMC Cancer; 2014 Jun; 14():450. PubMed ID: 24942472
[TBL] [Abstract][Full Text] [Related]
17. Nuclear p63 expression in osteoblastic tumors.
Kallen ME; Sanders ME; Gonzalez AL; Black JO; Keedy VL; Hande KR; Homlar KC; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Cates JM
Tumour Biol; 2012 Oct; 33(5):1639-44. PubMed ID: 22623071
[TBL] [Abstract][Full Text] [Related]
18. Osteoid osteoma and osteoblastoma: novel histological and immunohistochemical observations as evidence for a single entity.
Barlow E; Davies AM; Cool WP; Barlow D; Mangham DC
J Clin Pathol; 2013 Sep; 66(9):768-74. PubMed ID: 23814261
[TBL] [Abstract][Full Text] [Related]
19. β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma.
Wan Y; Zhao W; Jiang Y; Liu D; Meng G; Cai Y
Hum Pathol; 2014 Jul; 45(7):1459-65. PubMed ID: 24746516
[TBL] [Abstract][Full Text] [Related]
20. Borderline osteoblastic tumors: problems in the differential diagnosis of aggressive osteoblastoma and low-grade osteosarcoma.
Dorfman HD; Weiss SW
Semin Diagn Pathol; 1984 Aug; 1(3):215-34. PubMed ID: 6600112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
